News

Stop TB Partnership Craig David Video Series #3

In a newly released clip – the third in a series of videos shot in South Africa during his first country visit as a Goodwill Ambassador against Tuberculosis – British R&B star Craig David talks with Dr Sizulu Moyo, a tuberculosis researcher at Stellenbosch University.

Dr Sizulu Moyo

Dr Sizulu Moyo

Against the backdrop of a busy research laboratory, Craig learns that lots of progress has been made and momentum gained in the diagnosis and treatment of tuberculosis thanks to collaboration among partners as well as increased awareness and commitment from poor and rich countries alike, spurred by the link between tuberculosis and HIV/AIDS: tuberculosis is the leading infectious killer of people living with HIV.

Two key challenges mentioned by Dr Moyo are the need for sufficient funding to develop an effective vaccine and the need for tuberculosis patients to complete their course of treatment (which lasts 6 months or more) to keep the medicines effective: incomplete treatment will lead to the tuberculosis bacteria becoming drug-resistant. While people are aware that they should finish treatment, she explains, “it’s a complicated scenario; there are many things that come into play…We need understand where they are coming from. They are people with lives, with families.”

Despite her laboratory surroundings Dr Moyo remains very aware of the real-life implications of her research: “It’s not only about the documents that you read, any nice brochures, it’s not about the presentations that you make… TB affects real people, real families and real communities.”

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...